hotspot -WSS

hotspot

author：fashion 2025-10-04 04:00:35 - browse：95

An light blue number 3 with an eye is surrounded by smaller, black number 3s on an orange background — 3 to watch coverage from STAT — Christine Kao/STAT

It’s been a slow year for medtech. Major deals in 2023 were scarce, funding was hard to come by, and valuations were down. On the policy side, the industry grappled with changing AI regulations, reimbursement woes, and device sterilization rules.

Here are three political and market forces that shaped the medtech industry last year, and are worth paying attention to in 2024:

Lobbying power of AI, software-enabled devices

Medtech lobby AdvaMed announced earlier this month that the major medical imaging companies, previously housed within the National Electrical Manufacturers Association, were shifting to their shop. The device group also created a separate niche for digital health companies in October.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Victims of gun violence feel impacts long after bullet wound

explore

WSS

The Sacklers, horror, and ‘The Fall of the House of Usher’

Removing probiotics from the NICU could threaten preemies' health

The perfect storm of weather conditions that led to the devastating wildfires in Maui

GOP presidential candidates start declaring their loyalty

After John Oliver segment, STAT readers share their opioid

HPV cancer vaccine study demonstrates efficacy

leisure time

hotspot

Lobbying power of AI, software-enabled devices

Wikipedia

Peter Hotez and the public health issue of online harassment

White House calls on federal agencies to crack down on AI abuses

BioMarin wins approval for gene therapy to treat hemophilia A

House GOP releases memo on Hunter Biden foreign business dealings, reviving old claims

Tori Bowie and the unacceptable rates of Black maternal death

Senate panel clears PBM, hopsital reforms

How to save PrEP access — and even expand it

Excited delirium, Elijah McClain, and emergency physicians

Duchenne breakthrough therapy leaves behind pioneering families

House GOP releases memo on Hunter Biden foreign business dealings, reviving old claims

hotspot

HPV cancer vaccine study demonstrates efficacy

An innovative path out of biotech’s “valley of death”

Trump, Nauta plead not guilty to new classified docs charges but De Oliveira still not arraigned

Pharma budget tightening trickles down to Doximity

Novo acquires Inversago for up to $1 billion

Don't let 'shelved assets' gather dust. Make them into new lifesaving drugs

focus

explore

entertainment

focus